Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Return on Capital Employed came in at 21.91% in Q1 2026, up 1332.0% YoY from 1.53% in Q1 2025, and up 21.93% on a QoQ basis from 28.06% in Q4 2025.
Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 14 years of Return on Capital Employed data on file, last reported at 21.91% in Q1 2026.
- Quarterly Return on Capital Employed rose 1332.0% year-over-year to 21.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.91% (up 1332.0% YoY) and the FY2025 annual result came in at 30.47%, up 316.0% from the prior year.
- Return on Capital Employed rose to 21.91% in Q1 2026, from 28.06% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 21.91% in Q1 2026 to a low of 42.34% in Q1 2023.
- A 5-year average of 34.86% and a median of 35.31% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1465 bps — and 2026, when it soared 1332 bps.
- Tracing ENTA's Return on Capital Employed over 5 years: stood at 36.47% in 2022, then declined by 2 bps to 37.1% in 2023, then gained by 5 bps to 35.19% in 2024, then advanced by 20 bps to 28.06% in 2025, then advanced by 22 bps to 21.91% in 2026.
- The last three Return on Capital Employed figures came in at 21.91% (Q1 2026), 28.06% (Q4 2025), and 35.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -23.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.34% |
| Mar 31, 2026 | -21.91% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | -35.22% |
| Jun 30, 2025 | -36.20% |
| Mar 31, 2025 | -35.23% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -36.85% |
| Jun 30, 2024 | -35.31% |
| Mar 31, 2024 | -36.95% |
| Dec 31, 2023 | -37.10% |
| Sep 30, 2023 | -32.99% |
| Jun 30, 2023 | -38.88% |
| Mar 31, 2023 | -42.34% |
| Dec 31, 2022 | -36.47% |
| Sep 30, 2022 | -35.34% |
| Jun 30, 2022 | -34.99% |
| Mar 31, 2022 | -33.55% |
| Dec 31, 2021 | -31.78% |
| Sep 30, 2021 | -26.83% |